BridgeBio Pharma BBIO Asset turnover
Asset turnover at other companies
Other financials
Where this comes from
Calculated from BridgeBio Pharma’s reported figures.
Based on trailing twelve months.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's asset turnover.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's asset turnover?
- BridgeBio Pharma (BBIO) reported asset turnover of 0.5× in Q1 2026.
- How has BridgeBio Pharma's asset turnover changed year-over-year?
- BridgeBio Pharma's asset turnover increased by 249.8% year-over-year, from 0.1× to 0.5×.
- What is the long-term trend for BridgeBio Pharma's asset turnover?
- Over 4 years (2021 to 2025), BridgeBio Pharma's asset turnover has grown at a 60.7% compound annual growth rate (CAGR), from 0.1× to 0.5×.
- What does asset turnover mean?
- How many sales dollars the company generates from each dollar of assets.
- How do you interpret asset turnover?
- Higher turnover means a more sales-efficient asset base. Low-margin businesses (retail, distribution) compete on high turnover; high-margin ones (software, luxury) on margin.
- How does asset turnover compare across companies?
- Compare within an industry — turnover differences across sectors reflect business models, not performance.